Latest News

circulating levels of lymphocytes, platelets and neutrophils have been identified as factors related to unfavorable clinical outcome for many solid tumors. The aim of this cohort study is to evaluate and validate the use of the Prostatic Systemic Inflammatory Markers (PSIM) score in predicting and improving the detection of clinically significant prostate cancer (csPCa) in […]

Rationale: Novel radiopharmaceuticals for positron emission tomography (PET) are evaluated for the diagnosis of biochemically recurrent prostate cancer (BCR PC). Here, we compare the gastrin releasing peptide receptors (GRPR) – targeting 68Ga-RM2 with the prostate specific membrane antigen (PSMA) – targeting 68Ga-PSMA11 and 18F-DCFPyL.

Radiotherapy (RT) is an established, potentially curative treatment option for all risk constellations of localized prostate cancer (PCA). Androgen deprivation therapy (ADT) and dose-escalated RT can further improve outcome in high-risk (HR) PCA.

Artificial intelligence (AI) is the field of computer science that aims to build smart devices performing tasks that currently require human intelligence. Through machine learning (ML), the deep learning (DL) model is teaching computers to learn by example, something that human beings are doing naturally.

Muscle-invasive bladder cancer (MIBC) accounts for approximately 20% of all urothelial bladder carcinomas (UBC) at time of diagnosis, and up to 30% of patients with non-muscle invasive UBC will progress to MIBC over time.

Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa therapies.

(I) To evaluate the clinical efficacy of three different BCG strains in patients with intermediate-/high-risk non-muscle-invasive bladder cancer (NMIBC). (II) To determine the importance of performing routine secondary resection (re-TUR) in the setting of BCG maintenance protocol for the three strains.

(UroToday.com) At the risk stratification of non-muscle invasive bladder cancer (NMIBC)  through genomics and immunobiology session at the 2021 AUA Drug Development in NMIBC From Scientific, Regulatory, Clinician, and Patient Perspectives virtual meeting, Dr. Manjiri Dighe discussed the role of radiology and radiomics in staging and risk stratification of NMIBC.

(UroToday.com) At the American Urological Association (AUA)’s Drug Development in non-muscle-invasive bladder cancer (NMIBC) From Scientific, Regulatory, Clinician, and Patient Perspectives 2021 virtual meeting included a presentation by Dr. Max Kates discussing predictors for response to BCG therapy. 

(UroToday.com) The AUA’s Drug Development in non-muscle invasive bladder cancer (NMIBC) From Scientific, Regulatory, Clinician, and Patient Perspectives 2021 Virtual Meeting included a session on the treatment of non-muscle-invasive urothelial carcinoma of the upper tract and a presentation by Dr. Jennifer Taylor.